Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer

Lung Cancer

Volumn 98, Issue , 2016, Pages 76-78

  Boyer, Matthew J ^a   Gu, Lin ^b   Wang, Xiaofei ^b   Kelsey, Chris R ^a   Yoo, David S ^a   Onaitis, Mark W ^a   Dunphy, Frank R ^a   Crawford, Jeffrey ^a   Ready, Neal E ^a   Salama, Joseph K ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CANCER INSTITUTE   (United States)

Author keywords

Ipilimumab; Non small cell lung cancer; Radiation; Toxicity

Indexed keywords

CARBOPLATIN; CISPLATIN; IPILIMUMAB; PACLITAXEL; ANTINEOPLASTIC AGENT; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ACUTE TOXICITY; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ANOREXIA; ARTICLE; BACKACHE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DEHYDRATION; ESOPHAGITIS; FATIGUE; FEMALE; FOLLOW UP; HUMAN; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; ODYNOPHAGIA; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE CARE; POSTOPERATIVE RADIATION; PRIORITY JOURNAL; RADIATION DERMATITIS; RADIATION DOSE FRACTIONATION; RADIATION FIELD; RADIATION INJURY; RADIATION TOXICITY; RADIOTHERAPY UNIT; RETROSPECTIVE STUDY; SQUAMOUS CELL LUNG CARCINOMA; STEREOTACTIC BODY RADIATION THERAPY; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; ADJUVANT RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; LUNG TUMOR; MULTIMODALITY CANCER THERAPY; NON SMALL CELL LUNG CANCER; PROCEDURES; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; HUMANS; IPILIMUMAB; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSTOPERATIVE CARE; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 84973390002     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.05.014     Document Type: Article

References (8)

1. Albain K.S., et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009, 374(9687):379-386.
2. Bradley J.D., et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015, 16(2):187-199.
3. Lynch T.J., et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J. Clin. Oncol. 2012, 30(17):2046-2054.
4. Borghaei H., et al. Nivolumab versus docetaxel in advanced nonsquamous non-Small-Cell lung cancer. N. Engl. J. Med. 2015, 373(17):1627-1639.
5. Brahmer J., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 2015, 373(2):123-135.
6. Golden E.B., et al. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol. Res. 2013, 1(6):365-372.
7. Douillard J.Y., et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 2008, 72(3):695-701.
8. Lally B.E., et al. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance: epidemiology, and end results database. J. Clin. Oncol. 2006, 24(19):2998-3006.